CytomX Therapeutics (CTMX) news
Recent news
Cytomx TherA gets FDA fast track designation for Varseta-M
CytomX Therapeutics has announced plans for an upcoming meeting with the U.S. Food and Drug Administration (FDA) regarding its investigational therapy Varsetatug masetecan (Varseta-M) for the treatment of late-line metastatic colorectal cancer (mCRC). The company aims to align with the FDA on the…
AInvest Wire · 4d agoCytomX Therapeutics Q2 EPS USD -0.09
CytomX Therapeutics, Inc. (Nasdaq: CTMX) reported a net loss per share of -$0.09 for the second quarter of 2026, reflecting continued investment in its clinical-stage pipeline of PROBODY® therapeutics. The company’s Q2 2026 financial results showed a net loss of $18.2 million, or -$0.10 per share…
AInvest Wire · Aug 6, 2026Cytomx 2Q revenue $1.42M, estimate $6.93M
CytomX Therapeutics (NASDAQ: CTMX) reported second-quarter 2026 revenue of $1.42 million, significantly below the estimated $6.93 million . The company’s earnings per share (EPS) for the quarter was -$0.10, surpassing the consensus estimate of -$0.14 by $0.04. This performance reflects a continued…
AInvest Wire · Aug 6, 2026CytomX Therapeutics announces appointment of Charles Fuchs, M.D., M.P.H., to the board of directors
AInvest Wire · Jul 27, 2026CytomX: target nomination payment of $37M for two added targets
AInvest Wire · Jun 3, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.